European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.
Cite this article
Adjuvant treatment with a dialyzable leukocytes extract contributes to maintain HPV-infected women free of low-grade cervical lesions
A. Rodriguez-Flores1,*, G. Nuñez-Fernandez Nuñez-Fernandez2, I. Estrada-Garcia1, M. Aguilar-Santelises1,3, O. Rojas-Espinosa1, S. Estrada-Parra1
1 Department of Immunology, National School of Biological Sciences, IPN, Mexico City (Mexico)
2 Cervical Dysplasias Clinic, Angeles Hospital, México City (Mexico)
3 CMM, Karolinska Institute, Stockholm (Sweden)
Eur. J. Gynaecol. Oncol. 2015, 36(6), 655–661; https://doi.org/10.12892/ejgo2700.2015
Published: 10 December 2015
Purpose of investigation: To investigate if adjuvant treatment with a dialyzable extract of leukocytes (DLE), may help HPV-infected patients with low-grade intraepithelial squamous cervical lesions (LIS) to get free of HPV infection and cervical lesions. Materials and Methods: Patients with untreated, low-grade cervical lesions were treated either with surgery (Group A) or with DLE (Group B). Patients with low-grade but recurrent cervical lesions were newly treated with surgery plus DLE (Group C). Results: A decreased or absent cervical lesion correlated with a diminished or absent HPV viral load at one year of treatment (r = 0.6, p < 0.05). Seventy-nine percent of Group B but only 50 % of Group C and 38 % of Group A patients were free of cervical lesion after 24 months of treatment (p < 0.05). Conclusion: The present data support the benefit of adding DLE as adjuvant for treating HPV-infected women with LIS.
Dialyzable leukocytes extract
Low-grade cervical lesions